At Alfa Cytology, we offer a comprehensive suite of exosome services designed to accelerate cancer research and therapeutic development. As a preclinical CRO specializing in oncology, we provide end-to-end exosome solutions, from isolation and characterization to biomarker discovery, liquid biopsy, drug delivery, and personalized therapy research, empowering researchers and pharmaceutical companies to harness the full potential of exosomes in the fight against cancer.
Exosomes are small extracellular vesicles (30–150 nm in diameter) secreted by nearly all cell types, carrying a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids (DNA, mRNA, miRNA, lncRNA, and circRNA), that reflect the biological state of their parent cells. These naturally occurring nanoparticles serve as critical mediators of intercellular communication within the tumor microenvironment (TME), transferring molecular cargo between tumor cells, immune cells, and stromal cells to influence tumor progression, metastasis, angiogenesis, immune evasion, and drug resistance.
The unique characteristics of exosomes make them invaluable tools in cancer research and clinical translation:
Fig. 1 Exosomal roles in cancer growth and progression. (Sergazy S, et al.; 2025)
At Alfa Cytology, our exosome services are designed to support every stage of your cancer research and therapeutic development programs. From the initial isolation and characterization of exosomes to advanced multi-omics profiling, biomarker discovery, liquid biopsy development, drug delivery, and personalized therapy applications, we provide end-to-end solutions tailored to your specific research needs.
Leveraging our deep expertise in oncology and state-of-the-art facilities, we deliver high-quality, reproducible results that accelerate your projects from discovery to preclinical validation. Our exosome services include, but are not limited to:
Exosome Isolation and Characterization Service
Employing advanced technologies and rigorous analytical methods, our scientist excels in exosome isolation and characterization from diverse biofluids, including plasma, urine, ascites, and pleural effusion, ensuring high purity and reproducibility for downstream applications.
Exosome Omics Analysis Service
Integrating genomics, transcriptomics, proteomics, and lipidomics, our team excels in comprehensive molecular profiling of exosome cargo, enabling deep characterization of nucleic acids, proteins, and lipids from minimal sample inputs for cancer research.
Exosome-Based Biomarker Discovery Service
Utilizing high-throughput screening platforms and rigorous analytical methods, exosomal biomarkers are identified and validated from biofluids for non-invasive early cancer detection, prognosis prediction, and real-time treatment response monitoring.
Integrating advanced exosome isolation platforms with multi-dimensional bioinformatics, Alfa Cytology is decoding tumor heterogeneity through liquid biopsy, enabling early detection, patient stratification, and real-time monitoring of therapeutic efficacy.
Exosome-Based Drug Delivery Service
Leveraging the natural tumor-homing and barrier-crossing properties of exosomes, our team designs and develops tailored delivery systems for small molecules, siRNA, and mRNA, enabling effective cancer therapy with reduced off-target effects.
Exosome-Based Personalized Therapy Development Service
Translating precision medicine principles into exosome-based platforms, our team excels in enabling individualized treatment strategies through patient-derived exosome profiling, molecular characterization, and PDO/PDOX-based efficacy evaluation for predictive assessment.
Our exosome platforms are designed to support a diverse range of therapeutic modalities, enabling preclinical evaluation of anti-cancer strategies across multiple drug classes. Leveraging the unique properties of exosomes, low immunogenicity, natural tumor-homing, and barrier-crossing capabilities, we provide tailored delivery solutions for the following therapeutic modalities:
 Small Molecule |
 Therapeutic Antibody |
 Cell Therapy |
 Gene Therapy |
 Cancer Vaccine |
 Peptide Therapy |
 Nucleic Acid Therapeutics |
 Oncolytic Viral Therapy |
As a preclinical CRO specializing in oncology, our exosome platforms have been extensively validated across a broad spectrum of malignancies. We offer comprehensive service capabilities spanning biomarker discovery, targeted delivery, and personalized efficacy evaluation:
As a preclinical CRO specializing in oncology, we offer distinct advantages that set us apart in advancing your exosome-based research programs:
From discovery to delivery, Alfa Cytology is your trusted preclinical CRO partner in exosome-driven oncology innovation. With deep expertise in tumor biology and rigorous quality systems, we accelerate your exosome-based programs from concept to IND-enabling data with speed, precision, and reproducibility. Please don't hesitate to contact us to discuss your project requirements and receive a customized service proposal.
References
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.
